Renibus Therapeutics Inc’s Post

Day 2 of the 2023 Annual National Conference! Below is a panel of speakers who presented on digital therapeutics. Tune in for more coverage today! Pharmacy Benefit Management Institute #PBMI2023 Pharmacy Benefit Management Institute

Wrapping up the 19th Annual HD Therapeutics Conference 2024 with enlightening insights! Here's a brief recap from the final day of the conference. Stay tuned for more updates! #HDResearch #HuntingtonsDisease #ScientificAdvancements #HDAfrica

Last week we had our first whole ecosystem shutdown. A week where everyone was off at the same time - time to prioritise well-being, refresh, relax and spend valuable time with family & friends. Here’s a snapshot of how I spent my week M:M Bio Grey Wolf Therapeutics Pathios Therapeutics ThirtyFiveBio #summershutdown #wellbeingmatters

Agreed, the patient-centric approach is so important when it comes to treatments.

There are some great Healthcare Investor conferences taking place this week. Are you tuning in to #Barclays and #Leerink? Check out the video below to hear why you should!

United Therapeutics v. Liquidia Join us on November 28th, wherein Dr. Roshan Shreshta explores the Enablement, Written Description, and Anticipation: Takeaways from United Therapeutics v. Liquidia

Exciting insights from the 19th Annual HD Therapeutics Conference! Here's a brief recap of day one of the conference.  Stay tuned for more updates!  #HDResearch #HuntingtonsDisease #HDafrica

Eventful past few months Verve Therapeutics summarized in our 3Q financial results announced today: 1. heart-1 trial results of VERVE-101 selected for late-breaking science presentation American Heart Association 2023 scientific sessions 11/12 at 3:30 PM. Investor event at 6:30 PM (webcast here: https://lnkd.in/eQHU66R8) 2. FDA clears IND for VERVE-101 to treat US patients with heterozygous familial hypercholesterolemia in a Phase 1 trial 3. Collaboration with Eli Lilly and Company expands to include PCSK9 and ANGPTL3 programs after Lilly buys out Beam's previously-held product rights 4. $485.2M in cash, runway into 2026 https://lnkd.in/eWAucdKR

🚀𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐊𝐲𝐯𝐞𝐫𝐧𝐚 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐀𝐝𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐅𝐃𝐀 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤, 𝐈𝐏𝐎 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐨𝐫𝐢𝐳𝐨𝐧 🌐 𝗜𝗻 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, Kyverna Therapeutics accelerates into another FDA fast track following IPO plans. As KYV-101 moves through the clinical trial stage, Kyverna will have more regular and convenient communication with U.S. regulators thanks to the fast track tag—this time for refractory progressive multiple sclerosis. Additionally, if and when Kyverna files a new #drug application, it allows the #business to request for priority review, which shortens the FDA approval review period to six months. Recently, Kyverna was able to obtain a fast-track tag for myasthenia gravis and approve the entry of its autologous CD19-targeting cell treatment into a phase 2 open-label trial for #patients suffering from #multiplesclerosis. 𝑳𝒐𝒐𝒌 𝒂𝒕 𝒐𝒖𝒓 𝑪𝒐𝒓𝒓𝒆𝒍𝒂𝒕𝒆𝒅 𝑹𝒆𝒑𝒐𝒓𝒕👉:https://bit.ly/3RPw6Qb #FDAFastTrack #IPOJourney #BiotechAdvancement #healthcareinnovation #acceleratingsuccess #biopharma #prophecymarketinsights

Friction? What friction?! Some interesting questions popped up in an interview I did with CMO360 on the working relationship between CFO and CMO. I wouldn't call it points of friction per se, but rather finding the right balance between funding for optimal clinical execution while at the same time maximizing cash runway. Finding that balance is critical and even more so in capital funding environments like we're currently in. With that in mind, I'm fortunate to have a great CMO in Shaheen E Lakhan, MD, PhD, FAAN along with the rest of our Exec tam here at Click Therapeutics, Inc. See below for my thoughts on how CMO's can best collaborate with CFO's.